Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris

被引:5
|
作者
Brumfiel, Caitlin M. [1 ]
Patel, Meera H. [2 ]
Bell, Katheryn A. [1 ]
Cardis, Michael A. [3 ]
机构
[1] Georgetown Univ, Sch Med, 3900 Reservoir Rd, Washington, DC 20007 USA
[2] Creighton Univ, Sch Med, Phoenix Reg Campus, Phoenix, AZ USA
[3] Georgetown Univ Hosp, MedStar Washington Hosp Ctr, Dept Dermatol, Washington, DC 20007 USA
关键词
acne vulgaris; trifarotene; retinoid; randomized controlled trials; RETINOIDS; ADOLESCENTS; MANAGEMENT;
D O I
10.2147/TCRM.S286953
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Acne vulgaris is a common skin condition of the face and trunk that negatively impacts quality of life. Trifarotene is a new first-in-class fourth-generation topical retinoid that has been uniquely studied in the treatment of both facial and truncal acne. Through selective agonism of retinoic acid receptor (RAR)-gamma, the most predominant RAR isotype in the epidermis, trifarotene exerts more targeted, skin-specific effects than earlier generation retinoids. This narrative review summarizes all currently available literature regarding the use of trifarotene in acne vulgaris. We focus on efficacy, safety, and tolerability data and highlight quality of life outcomes and patient-reported satisfaction. Future clinical trials and the clinical applicability of this novel medication in the treatment of acne are also discussed.
引用
收藏
页码:755 / 763
页数:9
相关论文
共 50 条